Rhode 2010 — the foundational RCT
The double-blind trial that tied the clinical effect to the biology, in breast-reduction surgery.
The design
Published in Plastic & Reconstructive Surgery, this was a double-blind, placebo-controlled study: the control group received an identical but inactive device, controlling for the placebo effect that confounds so many pain studies. It remains the anchor trial for tPEMF in post-operative recovery.
What it measured
The trial tracked three things at once — patient-reported pain scores over the first hours and days, total narcotic consumption, and interleukin-1β (a primary inflammatory cytokine) measured directly in wound exudate. Each of those findings has its own deep-dive in this library: pain at one hour, the sustained effect by five hours, the narcotic reduction, and the IL-1β drop.
Why one trial matters this much
By moving pain, drug use, and a molecular inflammation marker together in the same blinded patients, Rhode 2010 connected the clinical effect to the nitric-oxide mechanism rather than to expectation. That linkage is what separates a real therapy from a placebo, and it is why later work in cardiac and wound care built on this foundation.
The study design
Breast-reduction surgery patients were randomized to active or sham device. The sham device was physically identical — same weight, same appearance, same indicator light behavior — but delivered no electromagnetic field. Neither patients nor treating staff knew which group each patient was in. Primary endpoints were post-operative pain (VAS scale) and narcotic analgesic consumption over 48 hours. Secondary endpoint was IL-1β concentration in wound drain exudate — a direct in-tissue measure of inflammation rather than a patient-reported outcome. This combination of a subjective primary endpoint with an objective molecular secondary is what makes the trial's conclusions so durable.
What this means in practice
For a patient recovering from breast surgery — or any soft-tissue surgical procedure — the Rhode 2010 result translates to a recovery that is meaningfully less painful in the first critical hours, with roughly half the opioid requirement. Less pain means earlier mobilization. Fewer opioids means less nausea, clearer thinking, and a lower addiction risk. The device sits over the dressing and runs on its own; the patient does not have to manage their pain primarily through pills.
Compared to the standard alternative
Standard post-operative pain management after breast surgery typically involves a scheduled NSAID (ibuprofen or ketorolac) plus opioids as needed. NSAIDs carry GI and bleeding risk in a fresh surgical wound. Opioids carry nausea, sedation, constipation, and dependence risk. The Rhode 2010 active group required roughly half the opioid dose with no adverse device effects reported. The comparison is not tPEMF versus nothing — it is tPEMF as an adjunct, reducing the drug burden without replacing the entire pain-management protocol.
Sources
- Rhode C, et al. Plast Reconstr Surg. 2010 — PEMF, IL-1β, and post-operative pain (breast reduction)
Related
Ready to put SofPulse to work?
SofPulse is available by prescription. Patients can order online and pay with pre-tax HSA/FSA dollars; clinicians can start prescribing in minutes.
For education only — not medical advice, and not a substitute for a clinician's judgment. SofPulse is available by prescription only. Reimbursement figures reflect the 2026 CMS Physician Fee Schedule and vary by locality, payer, and documentation.